Cibus (CBUS) Announces Proposed Public Offering of Class A Common Stock

Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that it intends to offer shares of its Class A common stock in an underwritten public offering. Cibus also expects to grant to the underwriters of the offering a 45-day option to purchase up to an additional 15% of the shares of Class A common stock offered in the underwritten public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Certain existing institutional and accredited investors and Rory Riggs, Cibus’ Chief Executive Officer, have indicated an interest in purchasing shares of Class A Common Stock in this offering. Because these indications of interest are not binding agreements or commitments to purchase, those certain existing investors and Mr. Riggs may elect not to purchase any shares in this offering, or the underwriters may elect not to sell any shares in this offering to those certain existing investors or Mr. Riggs.

Roth Capital Partners and A.G.P./Alliance Global Partners are acting as joint bookrunning managers for the offering.

Cibus intends to use the net proceeds from this offering to fund further development of new and improvement of existing seed traits, Trait Machine operations, and for working capital and general corporate purposes.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Waymo wins California approval to expand ride-hailing service